Novo Nordisk A/S is a Denmark-based healthcare company operating in the Biotechnology industry. The company focuses on the research, development, and commercialization of treatments for chronic diseases, particularly diabetes and obesity.

Founded in the early 20th century in Copenhagen, Novo Nordisk became a pioneer in insulin production and remains a global leader in metabolic disease care.

Its portfolio includes:

• Long- and short-acting insulin therapies.

• Glucose control medications for diabetes management.

• Injectable treatments for obesity and metabolic disorders, including semaglutide-based therapies.

• Insulin delivery devices and digital health tools.

Novo Nordisk operates in more than 80 countries and distributes products globally, with strong exposure to the United States and European healthcare markets.

The company emphasizes research and development, investing in next-generation therapies and digital health solutions to improve long-term disease management.

Performance is influenced by regulatory approvals, pricing dynamics in major healthcare markets, clinical-trial outcomes, and demand trends in diabetes and obesity treatments.

Novo Nordisk shares trade on the New York Stock Exchange (NYSE) under the ticker NVO.

History and Development

Novo Nordisk was founded in 1923 in Denmark with the goal of producing insulin for European patients.

In its early years, the company focused on improving insulin manufacturing and expanding access to diabetes treatment.

Throughout the 20th century, Novo Nordisk diversified into therapies for hemophilia, growth disorders, and other chronic conditions, while strengthening its global presence.

Over time, the company expanded internationally and invested heavily in clinical research and biotechnology innovation.

In recent years, Novo Nordisk has gained significant market attention due to the growth of its obesity-treatment portfolio, particularly semaglutide-based medications.

Today, the company is recognized as a leading biotechnology firm focused on chronic disease management, supported by ongoing research, product innovation, and global distribution capabilities.

Additional Information

Novo Nordisk A/S (Denmark) is listed on the NYSE and has a market capitalization of $169.97 billion, with shareholders equity totaling $34.09 billion.

The company employs approximately 45.000 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Novo Nordisk A/S reported $51.27 billion in revenue, generating net income of $18.11 billion.

Key financial metrics include a P/E ratio of 9.39, a price-to-book (P/B) ratio of 4.99, and a trailing twelve-month dividend yield of 4.83%.

The company trades under the ticker NVO.